Cited by 145Amyloidosis: Diagnosis, Treatment, OutcomesAlzheimer's disease research and treatmentsAmyotrophic Lateral Sclerosis Research

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

FDA approves patisiran to treat hereditary transthyretin amyloidosis

Wood, Heather·2018·Nature Reviews Neurology

DOI 10.1038/s41582-018-0065-0

Open this paper in CoChat — free account

Integrity signals

Registry

Crossref · 10.1038/s41582-018-0065-0

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Gene-silencing technology gets first drug approval after 20-year wait
Ledford, H. (2018) · Nature · doi:10.1038/d41586-018-05867-7 · Cited by 131
Treatment success in hereditary transthyretin amyloidosis
Fyfe, I. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0048-1 · Cited by 7

Show all 2 references

Sorted by citations

Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR–Cas gene editing
Cheng, Q., Wei, T., Farbiak, L., Johnson, L. T., Dilliard, S. A., & Siegwart, D. J. (2020) · Nature Nanotechnology · doi:10.1038/s41565-020-0669-6 · Cited by 2,383
Current hurdles to the translation of nanomedicines from bench to the clinic
Đorđević, S., Gonzalez, M. M., Conejos‐Sánchez, I., Carreira, B., Pozzi, S., Acúrcio, R. C., Satchi‐Fainaro, R., Florindo, H. F., & Vicent, M. J. (2021) · Drug Delivery and Translational Research · doi:10.1007/s13346-021-01024-2 · Cited by 715
“No other oligonucleotide-based nanomedicine has been developed and authorized at the same pace, considering, for example, the amyloidosis therapeutic Onpattro® (Patisiran) [10].”
Background
Systemic nanoparticle delivery of CRISPR-Cas9 ribonucleoproteins for effective tissue specific genome editing
Wei, T., Cheng, Q., Min, Y.-L., Olson, E. N., & Siegwart, D. J. (2020) · Nature Communications · doi:10.1038/s41467-020-17029-3 · Cited by 615
Naturally-occurring cholesterol analogues in lipid nanoparticles induce polymorphic shape and enhance intracellular delivery of mRNA
Patel, S., Ashwanikumar, N., Robinson, E., Xia, Y., Mihai, C., Griffith, J. P., Hou, S., Esposito, A. A., Ketova, T., Welsher, K., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14527-2 · Cited by 601
Epigenetic regulation in human cancer: the potential role of epi-drug in cancer therapy
Lu, Y., Chan, Y.-T., Tan, H., Li, S., Wang, N., & Feng, Y. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01197-3 · Cited by 521
“Patisiran Monotherapy Rare polyneuropathy FDA approved [136]”
Background
The growth of siRNA-based therapeutics: updated clinical studies
Zhang, M. M., Bahal, R., Rasmussen, T. P., Manautou, J. E., & Zhong, X.-B. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114432 · Cited by 497
Small and long non-coding RNAs: Past, present, and future
Chen, L., & Kim, V. N. (2024) · Cell · doi:10.1016/j.cell.2024.10.024 · Cited by 461
RNA Drugs and RNA Targets for Small Molecules: Principles, Progress, and Challenges
Yu, A., Choi, Y. H., & Tu, M. (2020) · Pharmacological Reviews · doi:10.1124/pr.120.019554 · Cited by 421
“The first siRNA drug, patisiran (Table 2), was approved by the FDA in 2018 for the treatment of the polyneuropathy of hATTR amyloidosis in adults (Wood, 2018; Yu et al., 2019) over 20 years after the discovery of siRNA-controlled gene silencing.”
BackgroundInfluential
Engineered ionizable lipid nanoparticles for targeted delivery of RNA therapeutics into different types of cells in the liver
Kim, M., Jeong, M., Hur, S., Cho, Y., Park, J., Jung, H. R., Seo, Y., Woo, H., Nam, K. T., Lee, K., et al. (2021) · Science Advances · doi:10.1126/sciadv.abf4398 · Cited by 397
“These drugs target the selective degradation of mRNA to reduce the expression of diseaseassociated proteins in polyneuropathy and acute hepatic porphyria (2, 5, 9).”
Background
Lipid-Nanoparticle-Based Delivery of CRISPR/Cas9 Genome-Editing Components
Kazemian, P., Yu, S.-Y., Thomson, S. B., Birkenshaw, A., Leavitt, B. R., & Ross, C. J. (2022) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.1c00916 · Cited by 363
Rekindling RNAi Therapy: Materials Design Requirements for In Vivo siRNA Delivery
Kim, B., Park, J., & Sailor, M. J. (2019) · Advanced Materials · doi:10.1002/adma.201903637 · Cited by 307
Lipid nanoparticle topology regulates endosomal escape and delivery of RNA to the cytoplasm
Zheng, L., Bandara, S. R., Tan, Z., & Leal, C. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2301067120 · Cited by 283
Development and Clinical Translation of Approved Gene Therapy Products for Genetic Disorders
Shahryari, A., Jazi, M. S., Mohammadi, S., Nikoo, H. R., Nazari, Z., Hosseini, E. S., Burtscher, I., Mowla, S. J., & Lickert, H. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00868 · Cited by 271
“Alnylam Pharmaceuticals, Inc. (Nasdaq), the leading RNAi therapeutics company, developed this lipid complex drug to treat familial amyloid polyneuropathy (FAP) in adults (Wood, 2018).”
Background
Genome Editing with mRNA Encoding ZFN, TALEN, and Cas9
Zhang, H., Zhang, Y., & Yin, H. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.01.014 · Cited by 256
“An LNP-encapsulated siRNA drug named patisiran has been approved by the FDA for treating ATTR amyloidosis with polyneuropathy.(168) It is worth noting that, although CRISPR is likely used to target the same protein as RNAi therapy, CRISPR-based therapy is not a “me too” drug.”
Background
In situ T-cell transfection by anti-CD3-conjugated lipid nanoparticles leads to T-cell activation, migration, and phenotypic shift
Kheirolomoom, A., Kare, A. J., Ingham, E. S., Paulmurugan, R., Robinson, E. R., Baikoghli, M., Inayathullah, M., Seo, J. W., Wang, J., Fite, B. Z., et al. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.121339 · Cited by 171
RNA therapy: Are we using the right molecules?
Yu, A., Jian, C., Yu, A. H., & Tu, M. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.11.011 · Cited by 167
“In addition, the most recent approval of first-of-its-kind double-stranded siRNA patisiran by the FDA (Wood, 2018), which was shown to improve multiple clinical manifestations of hereditary transthyretin amyloidosis (Adams et al.”
BackgroundInfluential
Silencing hepatic MCJ attenuates non-alcoholic fatty liver disease (NAFLD) by increasing mitochondrial fatty acid oxidation
Barbier‐Torres, L., Fortner, K. A., Iruzubieta, P., Delgado, T. C., Giddings, E. L., Chen, Y., Champagne, D., Fernández‐Ramos, D., Mestre, D., Gómez‐Santos, B., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16991-2 · Cited by 147
“The most common delivery system for siRNA to the liver has long been LNP and the ﬁ rst LNP-formulated siRNA-based drug (Patisiran) was approved in 2018 for the treatment of hATTR (hereditary transthyretin-mediated) amyloidosis 40 .”
Background
MicroRNAs in Alzheimer’s Disease: Diagnostic Markers or Therapeutic Agents?
Angelucci, F., Čechová, K., Vališ, M., Kuča, K., Zhang, B., & Hort, J. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00665 · Cited by 145
“In 2018, the FDA approved the first therapy based on administration of miRNA for the treatment of rare progressive polyneuropathy caused by hereditary transthyretin-mediated (hATTR) amyloidosis (Adams et al., 2018; Wood, 2018).”
Background
Nanomedicine-Based Approaches for mRNA Delivery
Uchida, S., Perche, F., Pichon, C., & Cabral, H. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00618 · Cited by 139
Integrating Combinatorial Lipid Nanoparticle and Chemically Modified Protein for Intracellular Delivery and Genome Editing
Chang, J., Chen, X., Glass, Z., Gao, F., Mao, L., Wang, M., & Xu, Q. (2018) · Accounts of Chemical Research · doi:10.1021/acs.accounts.8b00493 · Cited by 130
Securing the Payload, Finding the Cell, and Avoiding the Endosome: Peptide‐Targeted, Fusogenic Porous Silicon Nanoparticles for Delivery of siRNA
Kim, B., Sun, S., Varner, J. A., Howell, S. B., Ruoslahti, E. I., & Sailor, M. J. (2019) · Advanced Materials · doi:10.1002/adma.201902952 · Cited by 122
Viral and Non-Viral Systems to Deliver Gene Therapeutics to Clinical Targets
Taghdiri, M., & Mussolino, C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25137333 · Cited by 131
“A seminal study explored the use of LNP-mediated liver delivery of a siRNA targeted to treat transthyretin (TTR)-induced amyloidosis and was the first LNP-siRNA drug to achieve marketing approval in 2018 (Table 3) [115].”
Background
ADAMTS5 in Osteoarthritis: Biological Functions, Regulatory Network, and Potential Targeting Therapies
Jiang, L., Lin, J., Zhao, S., Wu, J., Jin, Y., Li, Y., Wu, N., Wu, Z., Wang, Y., & Lin, M. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.703110 · Cited by 122
“…and intrathecal delivery in hereditary transthyretin amyloidosis, cytomegalovirus retinitis, and spinal muscular atrophy treatment has provided perfect examples for a safe and efficient delivery of the therapeutic construct (Group, 2002; Aartsma-Rus, 2017; Wood, 2018; Gillmore et al., 2021).”
Background
Current RNA-based Therapeutics in Clinical Trials
Zhou, L., Qin, Z., Zhu, Y., He, Z., & Xu, T. (2019) · Current Gene Therapy · doi:10.2174/1566523219666190719100526 · Cited by 118
Progress and promises of epigenetic drugs and epigenetic diets in cancer prevention and therapy: A clinical update
Mondal, P., Natesh, J., Penta, D., & Meeran, S. M. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.12.006 · Cited by 91
Deliver the promise: RNAs as a new class of molecular entities for therapy and vaccination
Yu, A., & Tu, M. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107967 · Cited by 94
“1) (Wood, 2018).”
Background
Recent progress of polymeric nanogels for gene delivery
Kandil, R., & Merkel, O. M. (2019) · Current Opinion in Colloid & Interface Science · doi:10.1016/j.cocis.2019.01.005 · Cited by 84
RNA delivery biomaterials for the treatment of genetic and rare diseases
Zhao, W., Hou, X., Vick, O. G., & Dong, Y. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119291 · Cited by 82
Developing Small Activating RNA As a Therapeutic: Current Challenges and Promises
Kwok, A., Raulf, N., & Habib, N. (2019) · Therapeutic Delivery · doi:10.4155/tde-2018-0061 · Cited by 80
Tegsedi (Inotersen): An Antisense Oligonucleotide Approved for the Treatment of Adult Patients with Hereditary Transthyretin Amyloidosis
Gales, L. (2019) · Pharmaceuticals · doi:10.3390/ph12020078 · Cited by 80
Cationic Amphiphilic Drugs Boost the Lysosomal Escape of Small Nucleic Acid Therapeutics in a Nanocarrier-Dependent Manner
de Vyver, T. V., Bogaert, B., Backer, L. D., Joris, F., Guagliardo, R., Hoeck, J. V., Merckx, P., Calenbergh, S. V., Ramishetti, S., Peer, D., et al. (2020) · ACS Nano · doi:10.1021/acsnano.0c00666 · Cited by 77
Use of Microfluidics to Prepare Lipid-Based Nanocarriers
Vogelaar, A., Marcotte, S., Cheng, J., Oluoch, B., & Zaro, J. L. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15041053 · Cited by 76
“Efforts to optimize LNP systems for nucleic acid delivery led to the development of Onpattro (Patisiran) in 2018, marking the first FDA-approved treatment using small interfering RNA (siRNA), as well as the first FDA-approved LNP system [33].”
Background
Disruption of the NKG2A:HLA-E Immune Checkpoint Axis to Enhance NK Cell Activation against Cancer
Fisher, J. G., Doyle, A. D. P., Graham, L., Khakoo, S. I., & Blunt, M. D. (2022) · Vaccines · doi:10.3390/vaccines10121993 · Cited by 71
Therapeutic Gene Silencing Using Targeted Lipid Nanoparticles in Metastatic Ovarian Cancer
Singh, M. S., Ramishetti, S., Landesman‐Milo, D., Goldsmith, M., Chatterjee, S., Palakuri, R., & Peer, D. (2021) · Small · doi:10.1002/smll.202100287 · Cited by 67
Dual inhibition of endothelial miR-92a-3p and miR-489-3p reduces renal injury-associated atherosclerosis
Wiese, C. B., Zhong, J., Xu, Z., Zhang, Y., Solano, M. A. R., Zhu, W., Linton, M. F., Sheng, Q., Kon, V., & Vickers, K. C. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.01.023 · Cited by 64
Cardiac amyloidosis: An underdiagnosed/underappreciated disease
Manolis, A. S., Manolis, T. A., Manolis, T. A., & Melita, H. (2019) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2019.07.022 · Cited by 67
Challenges and strategies for the delivery of biologics to the cornea
Wels, M., Roels, D., Raemdonck, K., Smedt, S. C. D., & Sauvage, F. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.04.008 · Cited by 53
“This is illustrated with the approval of Onpattro, the first lipid based non-viral carrier loaded with siRNA, which is intravenously injected to treat polyneuropathy of hereditary transthyretinmediated amyloidosis [146].”
Background
Applications of RNA interference in the treatment of arthritis
Rai, M. F., Pan, H., Yan, H., Sandell, L. J., Pham, C. T. N., & Wickline, S. A. (2019) · Translational research · doi:10.1016/j.trsl.2019.07.002 · Cited by 54
Current Progress on MicroRNA-Based Gene Delivery in the Treatment of Osteoporosis and Osteoporotic Fracture
Sun, X. H., Guo, Q., Wei, W., Robertson, S. P., Yuan, Y., & Luo, X. (2019) · International Journal of Endocrinology · doi:10.1155/2019/6782653 · Cited by 50
“Recently, patisiran, a double-stranded siRNA, has been approved in the USA and EU for treating the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR) in adults [20].”
Background
Graphene oxide as a 2D platform for complexation and intracellular delivery of siRNA
de Lázaro, I., Vranic, S., Marson, D., Rodrigues, A. F., Buggio, M., Esteban-Arranz, A., Mazza, M., Posocco, P., & Kostarelos, K. (2019) · Nanoscale · doi:10.1039/c9nr02301a · Cited by 49
Modulation of intrinsic inhibitory checkpoints using nano‐carriers to unleash NK cell activity
Biber, G., Sabag, B., Raiff, A., Ben‐Shmuel, A., Puthenveetil, A., Benichou, J. I. C., Jubany, T., Levy, M., Killner, S., & Barda‐Saad, M. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202114073 · Cited by 45
“Several Food and Drug Administration (FDA) approved nanomedicines exist for selective cargo delivery, and recently, the first siRNA containing NP platform, Onpattro (patisiran), was granted FDA approval (Wood et al , 2018).”
RNA Therapeutics for Improving CAR T-cell Safety and Efficacy
Schaible, P., Bethge, W. A., Lengerke, C., & Haraszti, R. Á. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-2155 · Cited by 43
MicroRNA-targeting nanomedicines for the treatment of intervertebral disc degeneration
Genedy, H. H., Humbert, P., Laoulaou, B., Moal, B. L., Fusellier, M., Passirani, C., Visage, C. L., Guicheux, J., Lepeltier, É., & Clouet, J. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115214 · Cited by 38
Species-Specific miRNAs in Human Brain Development and Disease
Prodromidou, K., & Matsas, R. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00559 · Cited by 38
“The field currently progresses rapidly as in 2018 the FDA approved the first therapy based onmiRNA administration for the treatment of rare progressive polyneuropathy caused by hereditary transthyretinmediated amyloidosis (Adams et al., 2018; Wood, 2018).”
Background
Transthyretin Stabilization: An Emerging Strategy for the Treatment of Alzheimer’s Disease?
Saponaro, F., Kim, J. H., & Chiellini, G. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228672 · Cited by 35
“Food and Drug Administration for the treatment of hereditary transthyretin amyloidosis [102,103].”
Background
Diagnostic and Treatment Approaches Involving Transthyretin in Amyloidogenic Diseases
Park, G. Y., Jamerlan, A., Shim, K. H., & An, S. S. A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20122982 · Cited by 38
“Due to many practical difficulties of transplantation, one of the treatment options could be symptom management, which can be applied to both ATTRwt and ATTRv amyloidoses [95,96].”
Background
Advances in the diagnosis and treatment of transthyretin amyloidosis with cardiac involvement
Rigopoulos, A. G., Ali, M. N. L., Abate, E., Torky, A.-R. W., Matiakis, M., Mammadov, M., Melnyk, H., Vogt, A., Vecchis, R. D., Bigalke, B., et al. (2019) · Heart Failure Reviews · doi:10.1007/s10741-019-09776-3 · Cited by 36
“tients to better manage the condition [78].”
Rationally Designed Anti-CRISPR Nucleic Acid Inhibitors of CRISPR-Cas9
Barkau, C. L., O’Reilly, D., Rohilla, K. J., Damha, M. J., & Gagnon, K. T. (2019) · Nucleic Acid Therapeutics · doi:10.1089/nat.2018.0758 · Cited by 33
“Nucleic acid inhibitors are significantly smaller than known natural anti-CRISPR proteins [27,28] and should benefit from the lessons learned during therapeutic development of antisense oligonucleotides and small interfering RNAs [51], some of which have been recently FDA approved [52,53].”
Background
Posttranscriptional regulation of Nrf2 through miRNAs and their role in Alzheimer's disease
Kaundal, R. K., Datusalia, A. K., & Sharma, S. S. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.106018 · Cited by 32
Asymmetric trichotomous partitioning overcomes dataset limitations in building machine learning models for predicting siRNA efficacy
Monopoli, K. R., Korkin, D., & Khvorova, A. (2023) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2023.06.010 · Cited by 27
MicroRNAs in amyotrophic lateral sclerosis: from pathogenetic involvement to diagnostic biomarker and therapeutic agent development
Wang, L., & Zhang, L. (2020) · Neurological Sciences · doi:10.1007/s10072-020-04773-z · Cited by 26
Non-coding RNAs and their bioengineering applications for neurological diseases
Das, T., Das, T. K., Khodarkovskaya, A., & Dash, S. (2021) · Bioengineered · doi:10.1080/21655979.2021.2003667 · Cited by 24
“This drug works by targeting the 3ʹUTR region of transthyretin mRNA [241,242].”
Background
From bench side to clinic: Potential and challenges of RNA vaccines and therapeutics in infectious diseases
Pandey, M., Ojha, D., Bansal, S., Rode, A. B., & Chawla, G. (2021) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2021.101003 · Cited by 23
Single AAV-mediated CRISPR-Nme2Cas9 efficiently reduces mutant hTTR expression in a transgenic mouse model of transthyretin amyloidosis
Wen, J., Cao, T., Wu, J., Chen, Y., Zhi, S., Huang, Y., Zhen, P., Wu, G., Aagaard, L., Zhong, J., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.05.010 · Cited by 24
The development of tertiary amine cationic lipids for safe and efficient siRNA delivery
Lin, Z., Bao, M., Yu, Z., Xue, L., Ju, C., & Zhang, C. (2019) · Biomaterials Science · doi:10.1039/c9bm00494g · Cited by 23
Dysregulation of microRNA and Intracerebral Hemorrhage: Roles in Neuroinflammation
Kashif, H., Shah, D., & Sukumari‐Ramesh, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22158115 · Cited by 24
Research progress on non-protein-targeted drugs for cancer therapy
Zhang, Y., Lu, L., Song, F., Zou, X., Liu, Y., Zheng, X., Qian, J., Gu, C., Huang, P. C., & Yang, Y. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02635-y · Cited by 22
Long Non-Coding RNAs as Functional Codes for Oral Cancer: Translational Potential, Progress and Promises
Lei, C.-S., Kung, H.-J., & Shih, J.-W. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094903 · Cited by 20
Engineering CaP-Pickering emulsion for enhanced mRNA cancer vaccines via dual DC and NK activations
Wu, S., Zhou, Y., Asakawa, N., Wen, M., Sun, Y., Ming, Y., Song, T., Chen, W., Ma, G., & Xia, Y. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.07.051 · Cited by 19
Towards Self-Transfecting Nucleic Acid Nanostructures for Gene Regulation
Gudipati, S., Zhang, K., & Rouge, J. L. (2019) · Trends in biotechnology · doi:10.1016/j.tibtech.2019.01.008 · Cited by 19
Cellular secretion and cytotoxicity of transthyretin mutant proteins underlie late-onset amyloidosis and neurodegeneration
Ibrahim, R. B., Yeh, S.-Y., Lin, K., Ricardo, F., Yu, T., Chan, C., Tsai, J., & Liu, Y. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03357-1 · Cited by 19
Antisense and Functional Nucleic Acids in Rational Drug Development
Prof. Robert Penchovsky, D. R. N., Georgieva, A. V., Dyakova, V., Traykovska, M., & Pavlova, N. (2024) · Antibiotics · doi:10.3390/antibiotics13030221 · Cited by 19
Targeted delivery of small noncoding RNA for glioblastoma
Yoo, J. Y., Yeh, M., Kaur, B., & Lee, T. J. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.11.004 · Cited by 19
“Despite the numerous efforts over the last two decades, the first siRNA-based therapeutics, Onpattro (patisiran) by Alnylam Pharmaceuticals, was only approved by FDA in 2018 for the treatment of peripheral nerve disease, polyneuropathy, through siRNA against hereditary transthyretinmediated amyloidosis (hATTR) [80, 81…”
Background
Inhibition of PIM2 in liver cancer decreases tumor cell proliferation in vitro and in vivo primarily through the modulation of cell cycle progression
Kronschnabl, P., Grünweller, A., Hartmann, R. K., Aigner, A., & Weirauch, U. (2019) · International Journal of Oncology · doi:10.3892/ijo.2019.4936 · Cited by 20
“In addition, the fact that the first siRNA drug has obtained market approval most recently (52) clearly indicates the potential of siRNAs for oncogene-targeting therapies.”
Viral Mimicry as a Design Template for Nucleic Acid Nanocarriers
de la Fuente, I. F., Sawant, S. S., Tolentino, M. Q., Corrigan, P. M., & Rouge, J. L. (2021) · Frontiers in Chemistry · doi:10.3389/fchem.2021.613209 · Cited by 17
“Such studies culminated in 2018 with the success of Patisiran (ONPATTRO®), a liposomal vector developed by Alnylam Pharmaceuticals, as the first US Food and Drug Administration approved synthetic carrier of siRNA into cells (Adams et al., 2018; Hoy, 2018; Wood, 2018).”
Background
Potential of siRNA in COVID-19 therapy: Emphasis on in silico design and nanoparticles based delivery
Fopase, R., Panda, C., Rajendran, A. P., Uludağ, H., & Pandey, L. M. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1112755 · Cited by 16
“The nanoparticle-based siRNA formulation, known as Patisiran (ONPATTRO™) targets transthyretin mRNA and is used for the treatment of polyneuropathy in a hereditary form of transthyretin-mediated (hATTR) amyloidosis (Wood, 2018).”
Background
A Strategy Utilizing Protein–Protein Interaction Hubs for the Treatment of Cancer Diseases
Carels, N., Sgariglia, D., Vieira, M. G., Lima, C. R., Carneiro, F. R. G., da Silva, G. F., da Silva, F. A. B., Scardini, R., Tuszyński, J. A., de Andrade, C. V., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242216098 · Cited by 18
Treating brain diseases using systemic parenterally-administered protein therapeutics: Dysfunction of the brain barriers and potential strategies
Zaghmi, A., Drouin‐Ouellet, J., Brambilla, D., & Gauthier, M. A. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120461 · Cited by 17
The future of genetic medicines delivered via targeted lipid nanoparticles to leukocytes
Tarab‐Ravski, D., Stotsky‐Oterin, L., Elisha, A., Kundoor, G. R., Ramishetti, S., Hazan‐Halevy, I., Haas, H., & Peer, D. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.10.014 · Cited by 13
Lipid Nanoparticles as a Shuttle for Anti-Adipogenic miRNAs to Human Adipocytes
Schachner-Nedherer, A.-L., Fuchs, J., Vidaković, I., Höller, O., Schratter, G., Almer, G., Fröhlich, E., Zimmer, A., Wabitsch, M., Kornmueller, K., et al. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15071983 · Cited by 16
Enabling safer, more potent oligonucleotide therapeutics with bottlebrush polymer conjugates
Chen, P., Wei, Y., Sun, T., Lin, J., & Zhang, K. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.12.035 · Cited by 16
siRNA nanoparticle targeting Usp20 lowers lipid levels and ameliorates metabolic syndrome in mice
Ding, Y., Chen, Q., Xu, H., Adi, D., Ding, Y., Luo, W., Zhu, W.-Z., Xu, J.-C., Zhao, X., Shi, X., et al. (2024) · Journal of Lipid Research · doi:10.1016/j.jlr.2024.100626 · Cited by 14
“This drug was approved by the US Food and Drug Administration in 2018 for the treatment of hereditary amyloidogenic transthyretin amyloidosis (30).”
Background
The significance of bioengineered nanoplatforms against SARS-CoV-2: From detection to genome editing
Hassanzadeh, P. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119289 · Cited by 13
“Onpattro, a lipid NP-based siRNA drug, has paved the way for clinical translation of the lipid NP nanomedicines which contain nucleic acids for expressing or silencing the target genes [196,197].”
An insight of different classes of RNA-based therapeutic, nanodelivery and clinical status: Current landscape
Chatterjee, S., Bhattacharya, M., Lee, S., & Chakraborty, C. (2023) · Current Research in Biotechnology · doi:10.1016/j.crbiot.2023.100150 · Cited by 12
Current and Near-Future Technologies to Quantify Nanoparticle Therapeutic Loading Efficiency and Surface Coating Efficiency with Targeted Moieties
Tran, V., Nguyen, N., Renkes, S., Nguyen, K. T., Nguyen, T. P., & Alexandrakis, G. (2025) · Bioengineering · doi:10.3390/bioengineering12040362 · Cited by 15
“Some notable NPs for gene therapy are mRNA lipid nanoparticles (LNPs) for COVID vaccines from Pfizer and Moderna and Patirisan to treat hereditary transthyretin [12,13].”
SATB1 as oncogenic driver and potential therapeutic target in head & neck squamous cell carcinoma (HNSCC)
Panchal, O., Wichmann, G., Grenman, R. A., Eckhardt, L., Kunz‐Schughart, L. A., Franke, H., Dietz, A., & Aigner, A. M. (2020) · Scientific Reports · doi:10.1038/s41598-020-65077-y · Cited by 12
Combinational silencing of components involved in JAK/STAT signaling pathway
Bousoik, E., Mahdipoor, P., Alhazza, A., & Aliabadi, H. M. (2022) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2022.106233 · Cited by 11
Cellular Uptake Mechanism of Nucleic Acid Nanocapsules and Their DNA-Surfactant Building Blocks
Pal, S., de la Fuente, I. F., Sawant, S. S., Cannata, J. N., Wu, H., & Rouge, J. L. (2023) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.3c00104 · Cited by 10
Advances in RNA therapy for the treatment of autoimmune diseases
Zhang, Y., Zang, C., Mao, M., Zhang, M., Tang, Z., Chen, W., & Wu, Z. (2025) · Autoimmunity Reviews · doi:10.1016/j.autrev.2025.103753 · Cited by 12
Surface Design Options in Polymer- and Lipid-Based siRNA Nanoparticles Using Antibodies
Gabel, M., Knauss, A., Fischer, D., Neurath, M. F., & Weigmann, B. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232213929 · Cited by 13
Nucleotides Entrapped in Liposome Nanovesicles as Tools for Therapeutic and Diagnostic Use in Biomedical Applications
Cardador, C. M., Muehlmann, L. A., Coelho, C. M., Silva, L. P., Garay, A. V., Carvalho, A. M. D. S., Bastos, I. M. D., & Longo, J. P. F. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15030873 · Cited by 10
Silencing of Neuropilins and GIPC1 in pancreatic ductal adenocarcinoma exerts multiple cellular and molecular antitumor effects
Borchardt, H., Schulz, A., Datta, K., Muders, M. H., & Aigner, A. M. (2019) · Scientific Reports · doi:10.1038/s41598-019-51881-8 · Cited by 10
Disease-modifying therapy for proteinopathies: Can the exception become the rule?
Bitan, G. (2019) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2019.07.010 · Cited by 10
“Bind, cleave and leave”: multiple turnover catalysis of RNA cleavage by bulge–loop inducing supramolecular conjugates
Amirloo, B., Staroseletz, Y., Yousaf, S., Clarke, D. J., Brown, T. P., Aojula, H. S., Аркадьевна, З. М., & Bichenkova, E. V. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab1273 · Cited by 9
RNA therapeutics in cardiovascular medicine
Damase, T. R., & Cooke, J. P. (2025) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000001210 · Cited by 8
Identifying Cleaved and Noncleaved Targets of Small Interfering RNAs and MicroRNAs in Mammalian Cells by SpyCLIP
Zhang, Y., Teng, Y., Xiao, W., Xu, B., Zhao, Y., Li, W., & Wu, L. (2020) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2020.10.009 · Cited by 9
“Patisiran is the first FDA (US Food andDrug Administration)-approved siRNA drug to treat hereditary transthyretinmediated amyloidosis (hATTR) by silencing transthyretin.(10,11) Later, givosiran is approved by the FDA to treat adults with acute hepatic porphyria by silencing aminolevulinate synthase 1 (ALAS1).”
Background
Emerging Contribution of PancRNAs in Cancer
Mercatelli, N., Palombo, R., & Paronetto, M. P. (2020) · Cancers · doi:10.3390/cancers12082035 · Cited by 8
Cyanuric chloride as the basis for compositionally diverse lipids
Nardo, D., Akers, C., Cheung, N. E., Isom, C. M., Spaude, J. T., Pack, D. W., & Venditto, V. J. (2021) · RSC Advances · doi:10.1039/d1ra02425f · Cited by 8
How the initial discovery of modified RNA enabled evasion of innate immune responses and facilitated the development of RNA therapeutics
Sioud, M. (2023) · Scandinavian Journal of Immunology · doi:10.1111/sji.13282 · Cited by 8
IL-22: A key inflammatory mediator as a biomarker and potential therapeutic target for lung cancer
Xu, L., Cao, P., Wang, J., Zhang, P., Hu, S., Cheng, C., & Wang, H. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e35901 · Cited by 8
“Twenty years after the discovery of the RNA interference mechanism, the first siRNA drugs (including Patisiran, Givosiran, Lumasiran, Inclisiran, Vutrisiran) were approved for clinical use by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency from 2018 to 2022 [141,142].”
Background
Small interfering RNA (siRNA) based therapies for cancer treatment: A special focus on cervical cancer
Bavishi, L., Butani, S., & Patel, S. S. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.178198 · Cited by 8
Localized RNA interference therapy to eliminate residual lung cancer after incomplete microwave ablation
Cao, F., Wan, C., Xie, L., Qi, H., Shen, L., Chen, S., Song, Z., & Fan, W. (2019) · Thoracic Cancer · doi:10.1111/1759-7714.13079 · Cited by 7
Design and In Vitro Evaluation of Novel Cationic Lipids for siRNA Delivery in Breast Cancer Cell Lines
Vaidya, S., Jeengar, M. K., Wadaan, M. A., Mahboob, S., Kumar, P., Reece, L. M., Bathula, S. R., & Dutta, M. (2022) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2022/9231641 · Cited by 7
Retracted
Exploring the Potentials of Antibody–siRNA Conjugates in Tumor Cell Gene Silencing without Cationic Assistance
Liu, Y., Quan, Y., Mao, Q., Xu, R., & Tai, W. (2025) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.5c00212 · Cited by 6
The Efficacy and Safety of Polyethylene Glycol Cholesterol- and Tocopherol Polyethylene Glycol 1000 Succinate-Modified Transforming Growth Factor β1 Small Interfering RNA Lipid Nanoparticles in the Treatment of Paclitaxel-Resistant Non-Small-Cell Lung Cancer
Zeng, Z., Zeng, X., Li, X., Feng, Y., Kan, Y., Liu, X., & Zeng, Y. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16010075 · Cited by 6
Innovative Genoceuticals in Human Gene Therapy Solutions: Challenges and Safe Clinical Trials of Orphan Gene Therapy Products
Sharma, R. K. (2023) · Current Gene Therapy · doi:10.2174/1566523223666230911120922 · Cited by 6
Which Nanobasics Should Be Taught in Medical Schools?
Sunshine, J. C., & Paller, A. S. (2019) · The AMA Journal of Ethic · doi:10.1001/amajethics.2019.337 · Cited by 6
A era dos medicamentos de ARN interferência: o panorama clínico dos fármacos para silenciamento génico
Godinho, B. M. D. C., & Khvorova, A. (2020) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · doi:10.25758/set.2227 · Cited by 6
Nonviral vector system for cancer immunogene therapy
Nie, W., Chen, J., Wang, B., & Gao, X. (2022) · MedComm – Biomaterials and Applications · doi:10.1002/mba2.10 · Cited by 6
Real-Life Data of 2-Year Lumasiran Use in the DAILY-LUMA Cohort
Leclerc, A.-L. S., Cloarec, M., Knebelmann, B., Allard, L., Boyer, O., Cloarec, S., Dossier, C., Quintrec, M. L., Nobili, F., Stehlé, T., et al. (2024) · Kidney International Reports · doi:10.1016/j.ekir.2024.12.033 · Cited by 5

Authors: Wood, H.
Corresponding author: Wood, Heather
ORCID: Wood, Heather
Venue: Nature Reviews Neurology
Publisher: Springer Science and Business Media LLC
Published: 2018-08-29
Volume: 14
Issue: 10
Pages: 570-570
ISSN: 1759-4758 (ISSN-L)
1759-4766
DOI: 10.1038/s41582-018-0065-0
OpenAlex: W2888899523
Cited by: 145
References: 2
Citations by year: 2026: 9 · 2025: 12 · 2024: 12 · 2023: 22 · 2022: 14 · 2021: 23 · 2020: 20 · 2019: 28 · 2018: 5
FWCI: 6.64
Type: journal article
Language: en
Open access: closed
Licence: www.springernature.com/gp/researchers/text-and-data-mining (tdm)
www.springernature.com/gp/researchers/text-and-data-mining (vor)
Locations: Nature Reviews Neurology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Internal Medicine › Amyloidosis: Diagnosis, Treatment, Outcomes
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
Keywords: patisiran, hereditary transthyretin amyloidosis, RNA interference therapy, prealbumin, FDA drug approval, rare genetic disorders, antisense oligonucleotides, protein misfolding

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

FDA approves patisiran to treat hereditary transthyretin amyloidosis

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks